- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03953170
Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: James McCormick, DO
- Phone Number: 412-359-3091
- Email: James.mccormick@ahn.org
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who are undergoing temporary ileostomy (loop or end ileostomy) regardless of the indication or technique used (open or laparoscopy) as part of their regular standard of care
- Age- 18-80 years old
- Normal routine laboratories (CMP, CBC, CRP, amylase, lipase)
- Permitted medications will include biologicals which dose has not been changed for > 6 months, and immunosuppressant therapy which dose has not been changed for 3 months (i.e. codeine sulfate, loperamide, or Lomotil)
Exclusion Criteria:
- Emergency need for ileostomy
- Pregnant or nursing
- Malnutrition or requiring parenteral or enteral nutrition
- Known intestinal obstruction, stricture, or adhesions that would predispose the patient to the development of intestinal obstruction, perforation, hemorrhage, or intestinal abscess
- Intestinal fistulas or abscess proximal to the ostomy
- Small bowel resection greater than 50 cm.
- Clinically significant cardiovascular, renal, pulmonary, endocrine, immunologic, dermatology, neurological or psychiatric disorders
- Cholelithiasis or pancreatitis
- Family history of colorectal cancer or familial polyposis
- Cancer in the last 5 years
- History of HIV, Hepatitis B or C, or other acute systemic or intestinal infections requiring antibiotics
- Use of GLP1 analogues which may increase the risk of acute pancreatitis
- Treatment of Octreotide
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo
|
Active Comparator: Teduglutide
Teduglutide 0.05 g/kg/day
|
Teduglutide (Gattex, Shire) was approved by the FDA in 2012 for use in adult patients with short bowel syndrome requiring parenteral support only. The results of this study will not be used to justify a change of indication, or dose currently approved for Teduglutide, and will not be used to advertise the drug. This study meets all of the requirements for exemption from the IND regulations and an IND exemption has been confirmed by the FDA.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in daily 24 hr ileostomy collection
Time Frame: Change from time of surgery to 12 weeks
|
(mL/day)
|
Change from time of surgery to 12 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Teduglutide
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ileostomy - Stoma
-
Chang Gung Memorial HospitalConvaTect, TaiwanUnknownStoma Ileostomy | Stoma ColostomyTaiwan
-
Coloplast A/SCompleted
-
11 Heath and Technologies LimitedThe Cleveland ClinicUnknownIleostomy; Complications | Ileostomy - StomaUnited States
-
Massachusetts General HospitalRecruitingSurgery | Ileostomy - Stoma | Colostomy StomaUnited States
-
BBraun Medical SASRecruitingEnterostomy | Stoma Ileostomy | Stoma ColostomySpain
-
Hospital de BasurtoAlberto Loizate Totoricaguena; Pedro García AlonsoUnknownIleostomy; Complications | Ileostomy - Stoma | Stoma Ileostomy | Ileus ParalyticSpain
-
Coloplast A/SCompletedIleostomy - Stoma | Colostomy StomaDenmark, Sweden
-
University of Southern CaliforniaUnknownIleostomy - Stoma | Colostomy StomaUnited States
-
Coloplast A/SCompletedIleostomy - Stoma | Colostomy - StomaDenmark
-
Coloplast A/SCompletedColostomy Stoma | Ileostomy StomaDenmark
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States